Keyphrases
Antigen Presentation
22%
Apoptotic Cells
22%
Brain Tumor
67%
Cell-intrinsic
22%
Chemoimmunotherapy
22%
Chemotherapy
22%
Clinical Trials
22%
Comparator Study
22%
Conformal Radiotherapy
22%
Conventional Chemotherapy
10%
Conventional Radiation Therapy
22%
Diffuse Intrinsic Pontine Glioma
45%
Dying Tumor Cells
22%
Effective Therapy
22%
Epigenomic Features
22%
Frontline Therapy
22%
Frontline Treatment
22%
Genomic Features
22%
High Risk
22%
Historical Comparators
22%
Historical Controls
45%
Hypothesis-driven
22%
Immune Markers
22%
Immune Response
45%
Immunogenic Antigens
22%
Immunologic Therapy
45%
Indoleamine 2,3-dioxygenase 1 (IDO1)
45%
Indoximod
100%
Induced Mechanism
10%
Low Toxicity
22%
Mechanistic Prediction
22%
Median Overall Survival
22%
Newly Diagnosed
22%
Oral Inhibitors
22%
Overall Survival
67%
Overall Time
22%
Partial Fields
22%
Patient Outcomes
22%
Pediatric
22%
Pediatric Brain Tumor
100%
Pediatric Patients
32%
Phase 1 Study
22%
Prognostic Risk Stratification
22%
Progression-free Survival
45%
Prolonged Survival
10%
Proof of Concept Study
22%
Radioimmunotherapy
100%
Real Possibility
22%
Recurrent Brain Tumors
22%
Recurrent Ependymoma
22%
Recurrent GBM
22%
Recurrent Medulloblastoma
22%
Recurring
22%
Refractory Patients
22%
Single-arm Trial
22%
Solid Tumors
22%
Stratified Design
22%
Successful Outcome
22%
Temozolomide
22%
Temozolomide Chemotherapy
22%
Treating children
22%
Tumor
45%
Medicine and Dentistry
Antigen Presentation
22%
Arm
22%
Biological Marker
22%
Brain Tumor
90%
Chemoimmunotherapy
22%
Clinical Trial
22%
Conformal Radiotherapy
22%
Ependymoma
22%
Epigenomics
22%
Immune Response
45%
Immunotherapy
100%
Indoleamine 2,3 Dioxygenase
45%
Indoximod
100%
Low Drug Dose
22%
Medulloblastoma
22%
Neoplasm
45%
Overall Survival
90%
Pediatric Brain Tumor
100%
Pediatrics
22%
Pediatrics Patient
32%
Pontine Glioma
45%
Progression Free Survival
45%
Risk Stratification
22%
Solid Malignant Neoplasm
22%
Temozolomide
45%
Tumor Cell
22%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
20%
Brain Tumor
100%
Chemotherapy
49%
Clinical Trial
20%
Ependymoma
20%
Immunotherapy
100%
Indoleamine 2,3 Dioxygenase
40%
Indoximod
89%
Medulloblastoma
20%
Neoplasm
60%
Overall Survival
80%
Pontine Glioma
40%
Progression Free Survival
40%
Solid Malignant Neoplasm
20%
Temozolomide
40%